Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide

Area of Science:

• Cardiovascular Biology
• Transplantation Immunology
• Molecular Medicine

Background:

• Graft coronary arteriosclerosis, a major cause of allograft failure, involves smooth muscle cell proliferation and intimal thickening.
• Elevated cyclin-dependent kinase 2 (cdk2) kinase mRNA, a key regulator of cell cycle progression, is observed in the thickened intima of cardiac allografts.

Purpose of the Study:

• To investigate the therapeutic potential of inhibiting cdk2 kinase using antisense oligodeoxynucleotides (ODN) to prevent neointimal hyperplasia in cardiac allografts.

Main Methods:

• Gene transfer of antisense phosphorothioate oligodeoxynucleotide (ODN) against cdk2 kinase via hemagglutinating virus of Japan (HVJ)-liposome complex.
• Intraluminal delivery of ODN to inhibit intimal hyperplasia in murine heterotopic cardiac allografts.
• Assessment of neointimal formation and vascular cell adhesion molecule-1 expression at 30 days post-transplantation.

Main Results:

• Antisense cdk2 kinase ODN treatment significantly inhibited neointimal formation in cardiac allografts.
• Vascular cell adhesion molecule-1 expression was suppressed by antisense cdk2 kinase ODN.
• No inhibitory effects were observed with sense or scrambled ODN treatments.

Conclusions:

• Intraluminal administration of antisense ODN targeting cdk2 kinase effectively inhibits neointimal formation after cardiac transplantation.
• This strategy offers a potential therapeutic approach to combat graft coronary arteriosclerosis and enhance allograft survival.